ScholarX: Browsing ScholarWorks

Browsing by Felip, EnriquetaAuthor

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하

Sort by: In order: Results/Page Authors/Record:

Showing results 1 to 20 of 33

SCIESCOPUS

A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer

Planchard, David; Wolf, Jürgen; Solomon, Benjamin; Sebastian, Martin; Wermke, Martin; Heist, Rebecca S.; Sun, Jong-Mu; Min Kim, Tae; Reguart, Noemi; Sanmamed, Miguel F., et al.

ArticleIssue Date2024CitationLung Cancer, v.197PublisherElsevier Ireland Ltd

SCIESCOPUS

A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer open access

Riely, Gregory J.; Smit, Egbert F.; Ahn, Myung-Ju; Felip, Enriqueta; Ramalingam, Suresh S.; Tsao, Anne; Johnson, Melissa; Gelsomino, Francesco; Esper, Raymond; Nadal, Ernest, et al.

ArticleIssue Date2024CitationFUTURE ONCOLOGY, v.20, no.16, pp 1047 - 1055PublisherFUTURE MEDICINE LTD

SCIESCOPUS

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

Zhou, Caicun; Tang, Ke-Jing; Cho, Byoung Chul; Liu, Baogang; Paz-Ares, Luis; Cheng, Susanna; Kitazono, Satoru; Thiagarajan, Muthukkumaran; Goldman, Jonathan W.; Sabari, Joshua K., et al.

ArticleIssue Date2023CitationNEW ENGLAND JOURNAL OF MEDICINE, v.389, no.22, pp 2039 - 2051PublisherMASSACHUSETTS MEDICAL SOC

SCIESCOPUS

Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2

Cho, Byoung Chul; Wang, Yongsheng; Felip, Enriqueta; Cui, Jiuwei; Spira, Alexander I.; Neal, Joel W.; Baik, Christina; Marmarelis, Melina Elpi; Ichihara, Eiki; Lee, Jong-Seok, et al.

ArticleIssue Date2024CitationJOURNAL OF CLINICAL ONCOLOGY, v.42, no.16PublisherLIPPINCOTT WILLIAMS & WILKINS

SCIESCOPUS

Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A

Besse, Benjamin; Goto, Koichi; Wang, Yongsheng; Lee, Se-Hoon; Marmarelis, Melina E.; Ohe, Yuichiro; Bernabe Caro, Reyes; Kim, Dong-Wan; Lee, Jong-Seok; Cousin, Sophie, et al.

ArticleIssue Date2025CitationJournal of Thoracic OncologyPublisherElsevier Inc.

SCIESCOPUS

Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC

Cho, Byoung C.; Lu, Shun; Felip, Enriqueta; Spira, Alexander I.; Girard, Nicolas; Lee, Jong-Seok; Lee, Se-Hoon; Ostapenko, Yurii; Danchaivijitr, Pongwut; Liu, Baogang, et al.

ArticleIssue Date2024CitationNEW ENGLAND JOURNAL OF MEDICINEPublisherMASSACHUSETTS MEDICAL SOC

SCIESCOPUS

Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Nonsmall Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial (Previously presented at ESMO Congress 2023, FPN:LBA14, Byoung Chul Cho et al. - Reused with permission.)

Schuler, Martin; Cho, Byoung Chul; Felip, Enriqueta; Spira, Alexander; Girard, Niolas; Lee, Jong-Seok; Lee, Se-Hoon; Ostapenko, Yuriy; Danchaivijitr, Pongwut; Liu, Baogang, et al.

ArticleIssue Date2024CitationONCOLOGY RESEARCH AND TREATMENT, v.47, pp 260 - 261PublisherKARGER

SCIESCOPUS

Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study

Felip, Enriqueta; Cho, Byoung Chul; Gutierrez, Vanesa; Alip, Adlinda; Besse, Benjamin; Lu, Shun; Spira, Alexander I.; Girard, Nicolas; Califano, Raffaele; Gadgeel, Shirish M., et al.

ArticleIssue Date2024CitationJOURNAL OF CLINICAL ONCOLOGY, v.42, no.16PublisherLIPPINCOTT WILLIAMS & WILKINS

SCOPUSESCI

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial open access

Solomon, Benjamin J.; Dagogo-Jack, Ibiayi; Lee, Se-Hoon; Boyer, Michael J.; Ramalingam, Suresh S.; Carcereny, Enric; Felip, Enriqueta; Han, Ji-Youn; Hida, Toyoaki; Hughes, Brett G.M., et al.

ArticleIssue Date2024CitationJTO Clinical and Research Reports, v.5, no.7PublisherElsevier Inc.

SCIESCOPUS

Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1–Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial open access

Reck, Martin; Barlesi, Fabrice; Yang, James Chih-Hsin; Westeel, Virginie; Felip, Enriqueta; Özgüroğlu, Mustafa; Dols, Manuel Cobo; Sullivan, Richard; Kowalski, Dariusz M.; Andric, Zoran, et al.

ArticleIssue Date2024CitationJournal of Thoracic Oncology, v.19, no.2, pp 297 - 313PublisherElsevier Inc.

SCIESCOPUS

Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Cho, Byoung Chul; Lee, Jong Seok; Wu, Yi-Long; Cicin, Irfan; Dols, Manuel Cobo; Ahn, Myung-Ju; Cuppens, Kristof; Veillon, Rémi; Nadal, Ernest; Dias, Josiane Mourão, et al.

ArticleIssue Date2023CitationJournal of Thoracic Oncology, v.18, no.12, pp 1731 - 1742PublisherElsevier Inc.

SCIESCOPUS

Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study open access

Vokes, Everett E.; Mornex, Francoise; Sezer, Ahmet; Cheng, Ying; Fang, Jian; Baz, David Vicente; Cil, Timucin; Adjei, Alex A.; Ahn, Myung-Ju; Barlesi, Fabrice, et al.

ArticleIssue Date2024CitationJournal of Thoracic Oncology, v.19, no.2, pp 285 - 296PublisherElsevier Inc.

SCIESCOPUS

Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results

Gutierrez, Martin; Lam, Wei-Sen; Hellmann, Matthew D.; Gubens, Matthew A.; Aggarwal, Charu; Tan, Daniel Shao Weng; Felip, Enriqueta; Chiu, Joanne W. Y.; Lee, Jong-Seok; Yang, James Chih-Hsin, et al.

ArticleIssue Date2023CitationNature Medicine, v.29, no.7, pp 1718 - 1727PublisherNature Research

SCISCIESCOPUS

Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK plus NSCLC from ALTA-1L

Yang, James C. H.; Kim, Hye R.; Ahn, Myung-Ju; Han, Ji-Youn; Hochmair, Maximilian J.; Lee, Ki H.; Delmonte, Angelo; Garcia Campelo, Maria R.; Kim, Dong-Wan; Felip, Enriqueta, et al.

ArticleIssue Date2019CitationANNALS OF ONCOLOGY, v.30PublisherOXFORD UNIV PRESS

SCIESCOPUS

ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-treated MET exon 14 (METex14) Skipping NSCLC in the VISION Trial

Le, Xiuning; Garassino, Marina Chiara; Ahn, Myung-Ju; Felip, Enriqueta; Cortot, Alexis B.; Sakai, Hiroshi; Mazieres, Julien; Thomas, Michael; Viteri, Santiago; Conte, Pierfranco, et al.

ArticleIssue Date2024CitationJOURNAL OF THORACIC ONCOLOGY, v.19, no.7, pp E4 - E4PublisherELSEVIER SCIENCE INC

SCIESCOPUS

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations Results From the Phase II TROPION-Lung05 Study

Sands, Jacob; Ahn, Myung-Ju; Lisberg, Aaron; Cho, Byoung Chul; Blumenschein, George; Shum, Elaine; Tostivint, Elvire Pons; Goto, Yasushi; Yoh, Kiyotaka; Heist, Rebecca, et al.

ArticleIssue Date2025CitationJournal of Clinical Oncology, v.43, no.10PublisherLippincott Williams and Wilkins

SCIESCOPUS

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Ahn, Myung-Ju; Tanaka, Kentaro; Paz-Ares, Luis; Cornelissen, Robin; Girard, Nicolas; Pons-Tostivint, Elvire; Vicente Baz, David; Sugawara, Shunichi; Cobo, Manuel; Pérol, Maurice, et al.

ArticleIssue Date2025CitationJournal of Clinical Oncology, v.43, no.3PublisherLippincott Williams and Wilkins

SCIESCOPUS

Encorafenib plus binimetinib in patients with BRAF(V)(600)-mutant non-small cell lung cancer: Phase II PHAROS study design open access

Riely, Gregory J.; Ahn, Myung-Ju; Felip, Enriqueta; Ramalingam, Suresh S.; Smit, Egbert F.; Tsao, Anne S.; Alcasid, Ann; Usari, Tiziana; Wissel, Paul S.; Wilner, Keith D., et al.

ArticleIssue Date2022CitationFUTURE ONCOLOGY, v.18, no.7, pp 781 - 791PublisherFUTURE MEDICINE LTD

SCISCIESCOPUS

Barlesi, Fabrice; Garon, Edward B.; Kim, Dong-Wan; Felip, Enriqueta; Han, Ji-Youn; Kim, Joo-Hang; Ahn, Myung-Ju; Fidler, Mary Jo; Gubens, Matthew A.; de Castro, Gilberto, Jr., et al.

ArticleIssue Date2019CitationJOURNAL OF THORACIC ONCOLOGY, v.14, no.5, pp 793 - 801PublisherELSEVIER SCIENCE INC

SCIESCOPUS

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy open access

Yu, Helena A.; Goto, Yasushi; Hayashi, Hidetoshi; Felip, Enriqueta; Chih-Hsin Yang, James; Reck, Martin; Yoh, Kiyotaka; Lee, Se-Hoon; Paz-Ares, Luis; Besse, Benjamin, et al.

ArticleIssue Date2023CitationJournal of Clinical Oncology, v.41, no.35, pp 5363 - 5375PublisherLippincott Williams and Wilkins

1 2

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Browsing by Felip, EnriquetaAuthor

BROWSE